Search clinical trials for: Fesoterodine (Toviaz)

Total 77 results

Pfizer

Terminated

Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy

Urinary Bladder, Overactive
Weill Medical College of Cornell University
Pfizer

Completed

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia (Toviaz)

Bladder Outlet Obstruction

United States
Pfizer

Completed

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. (SOFIA)

Urinary Bladder, Overactive

Portugal, Spain, Turkey, Finland, Germany, Norway, Sweden, Slovakia, Italy, Austria, United Kingdom, Belgium, Denmark, Israel, Switzerland
Pfizer

Completed

Drug Use Investigation for Toviaz

Overactive Bladder (OAB)
Pfizer

Completed

Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy

Overactive Bladder | Urinary Incontinence

Slovakia
University of Alberta
Pfizer

Completed

A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

Overactive Bladder | Mild Cognitive Impairment

Canada
Washington University School of Medicine

Completed

Comparative Urine Proteomic Studies of Overactive Bladder in Humans

Overactive Bladder

United States
University of North Carolina, Chapel Hill
National Institute on Aging (NIA)

Completed

Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE) (URGE)

Urge Urinary Incontinence

United States
Pfizer

Completed

A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

Urinary Bladder, Overactive

Canada, United States, Germany, Russian Federation, Czechia, Egypt, Bulgaria, Finland, Hungary, Korea, Republic of, Mexico, Poland, South Africa, Sweden, Ukraine
Mayo Clinic

Terminated

Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate

Overactive Bladder

United States
Saint Thomas Health
Pfizer

Withdrawn

Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

Urinary Incontinence | Bladder Dysfunction

United States
Rambam Health Care Campus

Unknown

Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms

Urinary Bladder, Overactive

Israel
Pfizer

Completed

Toviaz Post Marketing Surveillance Study

Overactive Bladder

Korea, Republic of
Pfizer

Completed

Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder

Over Active Bladder

Philippines
Pfizer

Completed

Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients

Stress Urinary Incontinence

Denmark
Pfizer

Completed

A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Treatment of Overactive Bladder

United States
University of British Columbia
Pfizer; Vancouver Coastal Health; International Collaboration on Repair Discoveries

Completed

Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

Autonomic Dysreflexia

Canada
Stéphane Bolduc
Pfizer

Completed

Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. (FOXY2015)

Overactive Bladder

Canada
Pfizer

Completed

Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder

Urinary Bladder, Overactive

Portugal
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Fesoterodine on Urgency Episodes in Parkinson's Disease Population

Urinary Bladder, Overactive | Parkinson Disease

Canada
Pfizer

Completed

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Treatment of Overactive Bladder

United States
University of Pennsylvania
Pfizer

Completed

Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder (PfizerOABLUT)

Overactive Bladder

United States
Pfizer

Completed

Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers

Healthy

Belgium
Pfizer

Completed

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

Urinary Bladder, Neurogenic

Japan
Brigham and Women's Hospital
Medical University of Silesia

Completed

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

Urinary Incontinence | Urgency Urinary

United States
Stéphane Bolduc
Pfizer

Completed

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children (FOXY)

Overactive Bladder
The Cleveland Clinic
Pfizer

Unknown

Premarin Versus Toviaz for Treatment of Overactive Bladder

Overactive Bladder

United States
Pfizer

Completed

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Urinary Bladder, Neurogenic

France, United States, Spain, Korea, Republic of, United Kingdom, Malaysia, Taiwan, Finland, Japan, Lithuania, Italy, Turkey, Estonia, Slovakia, Belgium, Canada, Germany, Greece, India, Philippines, Poland, Russian Federation, South... and more
Pfizer

Completed

BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG

Neurogenic Detrusor Overactivity

Belgium
Pfizer

Completed

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Overactive Bladder

Korea, Republic of, United States, Denmark, Germany, Canada, Hungary, Poland, France, United Kingdom, Slovakia, Sweden, Mexico, Czech Republic, Finland, Italy, Lithuania, Argentina, Chile, Colombia, Egypt, Greece, Norway, Philippines, Russian Federation and more
Pfizer

Completed

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

Overactive Bladder

Costa Rica, United States, Korea, Republic of, Germany, Slovakia, Ukraine, Belgium, Poland, Czechia
Pfizer

Completed

Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer

Neurogenic Detrusor Overactivity

Belgium
Pfizer

Completed

A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers

Urinary Bladder, Overactive

Singapore
Pfizer

Completed

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

Overactive Bladder

Japan
Pfizer

Completed

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

Overactive Bladder

Korea, Republic of, Taiwan, Hong Kong, Japan
Pfizer

Completed

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency

United States
Pfizer

Completed

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Urinary Bladder, Overactive

United States
Pfizer

Terminated

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

Healthy

United States
Pfizer

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Overactive Bladder

Denmark, United States, Canada, Costa Rica, Belgium, Czech Republic, Colombia, Germany, Hungary, Korea, Republic of, Spain, Chile, Taiwan, India, Brazil, Singapore, Greece, Hong Kong, Italy, Sweden, Poland, South Africa, Malaysia, Rom... and more
Pfizer

Completed

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

Healthy

United States
Samsung Medical Center
Samsung Biomedical Research Institute

Completed

Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients

Overactive Bladder

Korea, Republic of
Smith & Nephew, Inc.

Completed

Research Study to Compare the Addition of Topaz Micro Debridement to the Standard of Care Surgery

Hip Pain Chronic | Greater Trochanteric Pain Syndrome

Australia
TRiCares GmbH

Recruiting

TRiCares Topaz Transfemoral Tricuspid Heart Valve Replacement System First In Human Trial (TRICURE)

Tricuspid Regurgitation

France, Belgium
Pfizer

Completed

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

Overactive Bladder | Neurogenic Detrusor Overactivity

United States
Pfizer

Completed

UK Study Assessing Flexible Dose Fesoterodine in Adults (SAFINA)

Urinary Bladder, Overactive

United Kingdom
Pfizer

Completed

Phase1, Single Dose, Crossover Study to Determine Bioequivalence

Healthy

Singapore
Pfizer

Completed

Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect

Food | Therapeutic Equivalency

Japan
Pfizer

Completed

This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder

Overactive Bladder
Abramson Cancer Center of the University of Pennsylvania

Completed

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Prostate Adenocarcinoma

United States
ArthroCare Corporation

Completed

Plantar Fasciosis Treatment Using Coblation

Plantar Fasciitis

United States

3

Subscribe